Total chemical synthesis of human interferon alpha‐2b via native chemical ligation

Interferon‐alpha (IFNα) is a cytokine that orchestrates innate and adaptive immune responses and potently inhibits proliferation of normal and tumor cells. These properties have warranted the use of IFNα in clinical practice for the treatment of several viral infections and malignancies. However, overexpression of IFNα leads to immunopathology observed in the context of chronic viral infections and autoimmune conditions. Thus, it is desirable to develop therapeutic approaches that aim at suppressing excessive IFNα production. To that end, artificial evolution of peptides from phage display libraries represents a strategy that seeks to disrupt the interaction between IFNα and its cell surface receptor and thus inhibit the ensuing biological effects. Mirror‐image phage display that screens peptide libraries against the D‐enantiomer is particularly attractive because it allows for identification of proteolysis‐resistant D‐peptide inhibitors. This approach, however, relies on the availability of chemically synthesized D‐IFNα composed entirely of D‐amino acids. Here, we describe the synthesis and biological properties of IFNα2b of 165 amino acid residues produced by native chemical ligation, which represents an important first step toward the discovery of D‐peptide antagonists with potential therapeutic applications. Copyright © 2015 European Peptide Society and John Wiley & Sons, Ltd.

[1]  Le Zhao,et al.  Mirror image proteins. , 2014, Current opinion in chemical biology.

[2]  A. Otaka,et al.  Chemical synthesis of biologically active monoglycosylated GM2-activator protein analogue using N-sulfanylethylanilide peptide. , 2013, Angewandte Chemie.

[3]  M. Pazgier,et al.  An ultrahigh affinity d-peptide antagonist Of MDM2. , 2012, Journal of medicinal chemistry.

[4]  Chong Li,et al.  D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms , 2010, Proceedings of the National Academy of Sciences.

[5]  Chong Li,et al.  A left-handed solution to peptide inhibition of the p53-MDM2 interaction. , 2010, Angewandte Chemie.

[6]  T. Kawakami,et al.  The use of a cysteinyl prolyl ester (CPE) autoactivating unit in peptide ligation reactions , 2009 .

[7]  S. Kent Total chemical synthesis of proteins. , 2009, Chemical Society reviews.

[8]  Stephen B. H. Kent,et al.  In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. , 2009 .

[9]  Judith N. Mandl,et al.  Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections , 2008, Nature Medicine.

[10]  V. Pascual,et al.  The innate immune system in SLE: type I interferons and dendritic cells , 2008, Lupus.

[11]  Michael S. Kay,et al.  Potent D-peptide inhibitors of HIV-1 entry , 2007, Proceedings of the National Academy of Sciences.

[12]  J. Langer Interferon at 50: New Molecules, New Potential, New (and Old) Questions , 2007, Science's STKE.

[13]  S. Pestka The Interferons: 50 Years after Their Discovery, There Is Much More to Learn* , 2007, Journal of Biological Chemistry.

[14]  L. Rönnblom,et al.  Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. , 2006, Arthritis and rheumatism.

[15]  Diego Jaitin,et al.  Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. , 2005, Journal of molecular biology.

[16]  L. Rönnblom,et al.  Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. , 2004, Arthritis and rheumatism.

[17]  D. Tough Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell Stimulation , 2004, Leukemia & lymphoma.

[18]  S. Kent,et al.  Total chemical synthesis of crambin. , 2004, Journal of the American Chemical Society.

[19]  F. Romerio,et al.  MEK and ERK inhibitors enhance the antiproliferative effect of interferon‐α2b , 2002 .

[20]  Ion Gresser,et al.  Type I interferons produced by dendritic cells promote their phenotypic and functional activation. , 2002, Blood.

[21]  T. Luft,et al.  IFN‐α enhances CD40 ligand‐mediated activation of immature monocyte‐derived dendritic cells , 2002 .

[22]  H A Scheraga,et al.  Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L. Rönnblom,et al.  Presence of cutaneous interferon-a producing cells in patients with systemic lupus erythematosus , 2001, Lupus.

[24]  R. de Waal Malefyt,et al.  IFN-α and IL-10 Induce the Differentiation of Human Type 1 T Regulatory Cells1 , 2001, The Journal of Immunology.

[25]  G Schreiber,et al.  New Structural and Functional Aspects of the Type I Interferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface* , 2000, The Journal of Biological Chemistry.

[26]  F. Romerio,et al.  Interferon- α 2b reduces phosphorylation and activity of MEK and ERK through a Ras / Raf -independent mechanism , 2000, British Journal of Cancer.

[27]  J. Weill,et al.  Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection. , 2000, The Journal of infectious diseases.

[28]  F. Romerio,et al.  IFN-α2b Reduces IL-2 Production and IL-2 Receptor Function in Primary CD4+ T Cells , 2000, The Journal of Immunology.

[29]  P. S. Kim,et al.  Inhibiting HIV-1 Entry Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket , 1999, Cell.

[30]  J. Griffin,et al.  Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Z. Bentwich,et al.  Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[32]  K. Pang,et al.  Type I IFNs enhance the terminal differentiation of dendritic cells. , 1998, Journal of immunology.

[33]  G. Foster,et al.  Are all Type I human interferons equivalent? , 1998, Journal of viral hepatitis.

[34]  H. Senn,et al.  The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. , 1997, Journal of molecular biology.

[35]  S. Spector,et al.  Human cytomegalovirus-associated immunosuppression is mediated through interferon-alpha. , 1997, Blood.

[36]  Lorenz M. Mayr,et al.  Identification of d-Peptide Ligands Through Mirror-Image Phage Display , 1996, Science.

[37]  C. Pace,et al.  How to measure and predict the molar absorption coefficient of a protein , 1995, Protein science : a publication of the Protein Society.

[38]  Å. Lernmark,et al.  Interferon Expression in the Pancreases of Patients With Type I Diabetes , 1995, Diabetes.

[39]  G. Allen,et al.  Nomenclature of the human interferon proteins. , 1994, Journal of interferon research.

[40]  Xiaojian Huang,et al.  Induction of type I diabetes by interferon-alpha in transgenic mice. , 1993, Science.

[41]  S. Pestka,et al.  Convenient assay for interferons , 1981, Journal of virology.

[42]  Changqing Li,et al.  Total chemical synthesis of human T-cell leukemia virus type 1 protease via native chemical ligation. , 2010, Biopolymers.

[43]  G. Schreiber,et al.  The receptor of the type I interferon family. , 2007, Current topics in microbiology and immunology.

[44]  B. Beutler,et al.  TYPE I INTERFERONS (/) IN IMMUNITY AND AUTOIMMUNITY , 2005 .

[45]  B. Beutler,et al.  Type I interferons (alpha/beta) in immunity and autoimmunity. , 2005, Annual review of immunology.

[46]  T. Luft,et al.  IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. , 2002, International immunology.

[47]  F. Romerio,et al.  MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-alpha2b. , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  R. de Waal Malefyt,et al.  IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. , 2001, Journal of immunology.

[49]  P. Dawson,et al.  Synthesis of native proteins by chemical ligation. , 2000, Annual review of biochemistry.

[50]  F. Romerio,et al.  IFN-alpha 2b reduces IL-2 production and IL-2 receptor function in primary CD4+ T cells. , 2000, Journal of immunology.

[51]  T. Muir,et al.  Synthesis of proteins by native chemical ligation. , 1994, Science.

[52]  Kirk A Easley,et al.  Serum beta 2-microglobulin and interferon in homosexual males: relationship to clinical findings and serologic status to the human T lymphotropic virus (HTLV-III). , 1984, AIDS research.